The pseudoginsenoside F11 ameliorates cisplatin-induced nephrotoxicity without compromising its anti-tumor activity in vivo

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Wang, Hongbo ^a   Kong, Liang ^a   Zhang, Jianqiao ^a   Yu, Guohua ^c   Lv, Guangyao ^a   Zhang, Fangxi ^a   Chen, Xiaoguang ^b   Tian, Jingwei ^a   Fu, Fenghua ^a  

^a YANTAI UNIVERSITY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CISPLATIN; GINSENOSIDE; PSEUDOGINSENOSIDE;

ACUTE KIDNEY FAILURE; ANIMAL; APOPTOSIS; ARTICLE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG SCREENING; KIDNEY TUBULE; LEWIS CARCINOMA; MALE; MELANOMA; METABOLISM; METHODOLOGY; MOUSE; RAT; SPRAGUE DAWLEY RAT;

ACUTE KIDNEY INJURY; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, LEWIS LUNG; CISPLATIN; GINSENOSIDES; KIDNEY TUBULES; MALE; MELANOMA; MICE; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901008712     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04986     Document Type: Article

References (28)

1. Boulikas, T. &Vougiouka, M. Cisplatin and platinum drugs at the molecular level. (Review) Oncol Rep 10, 1663-1682 (2003).
2. Bose, R. N. Biomolecular targets for platinum antitumor drugs. Mini Rev Med Chem 2, 103-111 (2002).
3. Arany, I. & Safirstein, R. L. Cisplatin nephrotoxicity. Semin Nephrol 23, 460-464 (2003). (Pubitemid 37176691)
4. Perazella, M. A. &Moeckel, G. W. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 30, 570-581 (2010).
5. Yao, X., Panichpisal, K., Kurtzman, N. & Nugent, K. Cisplatin nephrotoxicity: a review. Am J Med Sci 334, 115-124 (2007). (Pubitemid 47262919)
6. Atessahin, A., Yilmaz, S., Karahan, I., Ceribasi, A. O. & Karaoglu, A. Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology 212, 116-123 (2005). (Pubitemid 40981968)
7. Pabla, N. & Dong, Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73, 994-1007 (2008). (Pubitemid 351543900)
8. Kannan, K. & Jain, S. K. Oxidative stress and apoptosis. Pathophysiology 7, 153-163 (2000).
9. Florea, A. M. & Busselberg, D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 3, 1351-1371 (2011).
10. Miyaji, T., Kato, A., Yasuda, H., Fujigaki, Y. & Hishida, A. Role of the increase in p21 in cisplatin-induced acute renal failure in rats. J Am Soc Nephrol 12, 900-908 (2001). (Pubitemid 32378330)
11. Humanes, B. et al. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int 82, 652-663 (2012).
12. Satoh, M. et al. A novel free radical scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo. J Pharmacol Exp Ther 305, 1183-1190 (2003). (Pubitemid 36617997)
13. Lee, K. W. et al. Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. Toxicology 257, 137-143 (2009).
14. Attele, A. S., Wu, J. A. & Yuan, C. S. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58, 1685-1693 (1999). (Pubitemid 29505408)
15. Sood, A. & Moynihan, T. J. Cancer-related fatigue: an update. Curr Oncol Rep 7, 277-282 (2005). (Pubitemid 41149673)
16. Wang, H. et al. Cardioprotective Effects of 20(S)-Ginsenoside Rh2 against Doxorubicin-Induced Cardiotoxicity In Vitro and In Vivo. Evid Based Complement Alternat Med 2012, 506214 (2012).
17. Fu, X. et al. Protective effect of ocotillol against doxorubicininduced acute and chronic cardiac injury. Mol Med Rep 9, 360-364 (2014).
18. Chen, R. J., Chung, T. Y., Li, F. Y., Lin, N. H. & Tzen, J. T. Effect of sugar positions in ginsenosides and their inhibitory potency on Na1/K1-ATPase activity. Acta Pharmacol Sin 30, 61-69 (2009).
19. Edelstein, C. L. Biomarkers of acute kidney injury. Adv Chronic Kidney Dis 15, 222-234 (2008). (Pubitemid 351822595)
20. Ravi, R., Somani, S. M. & Rybak, L. P. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 76, 386-394 (1995).
21. Cetin, R. et al. Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J Appl Toxicol 26, 42-46 (2006). (Pubitemid 43171334)
22. Yousef, M. I., Saad, A. A. & El-Shennawy, L. K. Protective effect of grape seed proanthocyanidin extract against oxidative stress induced by cisplatin in rats. Food Chem Toxicol 47, 1176-1183 (2009).
23. Yu, C., Fu, F., Yu, X., Han, B. & Zhu, M. Cardioprotective effect of ocotillol, a derivate of pseudoginsenoside F11, on myocardial injury induced by isoproterenol in rats. Arzneimittelforschung 57, 568-572 (2007). (Pubitemid 47555812)
24. Camano, S. et al. Cilastatin attenuates cisplatin-induced proximal tubular cell damage. J Pharmacol Exp Ther 334, 419-429 (2010).
25. Silke, J. et al. The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3-and caspase 9-interacting sites. J Cell Biol 157, 115-124 (2002). (Pubitemid 34847834)
26. Carvalho Rodrigues, M. A., Silva Faria, M. C., Santos, N. A., Gobe, G. C. & dos Santos, A. C. Carvedilol efficiently protects kidneys without affecting the antitumor efficacy of cisplatin in mice. Chem Biol Interact 206, 90-99 (2013).
27. Wang, H., Ma, X., Ren, S., Buolamwini, J. K. & Yan, C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther 10, 69-79 (2011).
28. Huang, D. et al. Anti-tumor activity of a 3-oxo derivative of oleanolic acid. Cancer Lett 233, 289-296 (2006). (Pubitemid 43327385)